Eli Lilly and Peptron maintain only a non-exclusive evaluation agreement, signed in late 2024 and extended into 2026, focused on applying the SmartDepot sustained-release microsphere platform to peptide candidates for internal research. No commercial licensing, technology transfer, or binding deal has been announced despite ongoing joint work. Recent Lilly moves toward oral obesity formulations and partnerships with alternative long-acting technologies, such as Camurus, have reinforced trader views that rapid progression to a full license is improbable before the early-October deadline. With roughly seven weeks remaining and typical pharma negotiation timelines, the 87.5% market-implied probability for “No” reflects consensus that the evaluation phase will not convert in time.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado13% probabilidad
$11,264 Vol.
$11,264 Vol.
7 oct 2026
13% probabilidad
$11,264 Vol.
$11,264 Vol.
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain only a non-exclusive evaluation agreement, signed in late 2024 and extended into 2026, focused on applying the SmartDepot sustained-release microsphere platform to peptide candidates for internal research. No commercial licensing, technology transfer, or binding deal has been announced despite ongoing joint work. Recent Lilly moves toward oral obesity formulations and partnerships with alternative long-acting technologies, such as Camurus, have reinforced trader views that rapid progression to a full license is improbable before the early-October deadline. With roughly seven weeks remaining and typical pharma negotiation timelines, the 87.5% market-implied probability for “No” reflects consensus that the evaluation phase will not convert in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain only a non-exclusive evaluation agreement, signed in late 2024 and extended into 2026, focused on applying the SmartDepot sustained-release microsphere platform to peptide candidates for internal research. No commercial licensing, technology transfer, or binding deal has been announced despite ongoing joint work. Recent Lilly moves toward oral obesity formulations and partnerships with alternative long-acting technologies, such as Camurus, have reinforced trader views that rapid progression to a full license is improbable before the early-October deadline. With roughly seven weeks remaining and typical pharma negotiation timelines, the 87.5% market-implied probability for “No” reflects consensus that the evaluation phase will not convert in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron maintain only a non-exclusive evaluation agreement, signed in late 2024 and extended into 2026, focused on applying the SmartDepot sustained-release microsphere platform to peptide candidates for internal research. No commercial licensing, technology transfer, or binding deal has been announced despite ongoing joint work. Recent Lilly moves toward oral obesity formulations and partnerships with alternative long-acting technologies, such as Camurus, have reinforced trader views that rapid progression to a full license is improbable before the early-October deadline. With roughly seven weeks remaining and typical pharma negotiation timelines, the 87.5% market-implied probability for “No” reflects consensus that the evaluation phase will not convert in time.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes